Zinc and Green Tea Extract for Community Respiratory Viral Infections (NCT04898023) | Clinical Trial Compass
TerminatedPhase 2
Zinc and Green Tea Extract for Community Respiratory Viral Infections
Stopped: Loss of funding
United States17 participantsStarted 2022-09-21
Plain-language summary
Zinc and green tea supplementation have both been independently studied for supporting immune health during cold and flu-like illness in non-hospitalized patients with clinical trials demonstrating promising but inconsistent results. Combination therapy may offer an improved effect as the antioxidant compounds found in green tea have been shown to increase cellular zinc concentrations thereby inhibiting viral replication. This study seeks to evaluate the effect of combination supplementation using established doses of zinc and green tea extract on symptom duration and severity from cold and flu-like illness, including COVID-19, in adult community patients enrolled in a randomized placebo-controlled trial.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
ā. Provision of signed and dated informed consent form
ā. Stated willingness to comply with all study procedures and availability for the duration of the study
ā. Male or female, aged 18 years and older
ā. Ability to take oral medication and be willing to adhere to the prescribed dosing regimen
ā. Self-reported cold or flu symptoms for \< 72 hours
Exclusion criteria
ā. Pregnant or actively seeking to become pregnant
ā. Positive for influenza with planned treatment with oseltamivir or baloxavir
ā. Current or planned treatment with an FDA regulated drug (including those under EUA) for COVID-19
ā. Chronic liver disease (i.e. baseline liver function tests (LFTs) \> 1.5x the upper limit of normal (ULN) or established cirrhosis
ā
What they're measuring
1
Number of Patients Who Recovered From Cold and Flu-like Symptoms